Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Recruiting 1 Approved for marketing 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 429 Breast Neoplasms 298 Neoplasms 296 Colorectal Neoplasms 242 Neoplasm Metastasis 197 Ovarian Neoplasms 171 Lung Neoplasms 150 Recurrence 147 Prostatic Neoplasms 146 Pancreatic Neoplasms 142 Multiple Myeloma 136 Stomach Neoplasms 129 Squamous Cell Carcinoma of Head and Neck 128 Melanoma 123 Leukemia, Myeloid, Acute 115 Endometrial Neoplasms 115 Advanced Solid Tumors 113 Advanced Solid Tumor 108 Carcinoma, Hepatocellular 102 Triple Negative Breast Neoplasms 101 Small Cell Lung Carcinoma 88 Uterine Cervical Neoplasms 86 Lymphoma, Non-Hodgkin 83 Carcinoma, Renal Cell 72 Lymphoma, Follicular 71 Lymphoma 67 Leukemia, Lymphocytic, Chronic, B-Cell 65 Solid Tumor 64 Lymphoma, Large B-Cell, Diffuse 64 Hematologic Neoplasms 62

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × GIST × Clear all

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡